Merck (MRK) Long-Term Deferred Tax (2010 - 2023)
Merck (MRK) posted quarterly Long-Term Deferred Tax of $10.2 billion for Q2 2023, down 7.15% year-over-year from $11.0 billion in Q2 2022, and down 0.9% quarter-over-quarter from $10.3 billion in Q1 2023.
Merck (MRK) Long-Term Deferred Tax (2010 - 2023) Analysis & Trends
Merck (MRK) has reported Long-Term Deferred Tax for 14 consecutive years, with $10.2 billion the latest figure, recorded in Q2 2023.
- In Q2 2023, Long-Term Deferred Tax fell 7.15% year-over-year to $10.2 billion; the TTM figure through Jun 2023 stood at $10.2 billion (down 7.15% YoY), while the FY2022 annual figure was $9.5 billion, down 17.73% from the prior year.
- Long-Term Deferred Tax declined to $10.2 billion in Q2 2023 per MRK's latest filing, from $10.3 billion in the prior quarter.
- Across five years, Long-Term Deferred Tax topped out at $11.6 billion in Q4 2021 and bottomed at $6.8 billion in Q4 2019.
- Historically, Long-Term Deferred Tax has averaged $9.6 billion across 5 years, with a median of $9.7 billion in 2020.
- Annual changes were most pronounced in 2020 — Long-Term Deferred Tax decreased 19.01% — and 2021, when it surged 48.7%.
- Merck's Long-Term Deferred Tax stood at $6.8 billion in 2019, then jumped by 45.93% to $9.9 billion in 2020, then grew by 17.21% to $11.6 billion in 2021, then slipped by 17.73% to $9.5 billion in 2022, then climbed by 6.92% to $10.2 billion in 2023.
- Business Quant data shows MRK's Long-Term Deferred Tax at $10.2 billion in Q2 2023, $10.3 billion in Q1 2023, and $9.5 billion in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 10.19 Bn |
| Mar 31, 2023 | 10.28 Bn |
| Dec 31, 2022 | 9.53 Bn |
| Sep 30, 2022 | 9.58 Bn |
| Jun 30, 2022 | 10.97 Bn |
| Mar 31, 2022 | 11.14 Bn |
| Dec 31, 2021 | 11.58 Bn |
| Sep 30, 2021 | 11.19 Bn |
| Jun 30, 2021 | 11.05 Bn |
| Mar 31, 2021 | 10.49 Bn |
| Dec 31, 2020 | 9.88 Bn |
| Sep 30, 2020 | 8.01 Bn |
| Jun 30, 2020 | 7.60 Bn |
| Mar 31, 2020 | 7.05 Bn |
| Dec 31, 2019 | 6.77 Bn |
| Sep 30, 2019 | 9.00 Bn |
| Jun 30, 2019 | 9.16 Bn |
| Mar 31, 2019 | 8.71 Bn |
| Dec 31, 2018 | 5.88 Bn |
| Sep 30, 2018 | 7.50 Bn |